At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 264 enrolled
Drug / intervention
IVX-A12 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a Randomized, Observer-blind, Placebo-controlled, Dosage Optimization, Multi-center Clinical Trial to Evaluate the Safety and Immunogenicity of IVX-A12, a Respiratory Syncytial Virus and Human Metapneumovirus Bivalent Combination Virus-like Particle Protein Subunit Vaccine, in Adults 60 to 85 Years of Age
In Brief
A Phase 2 clinical trial evaluating IVX-A12 and Placebo for Healthy. Completed, enrolled 264 participants across 10 sites.
Detailed Summary
The primary purpose of the study is to assess the safety, tolerability and immunogenicity of a bivalent respiratory syncytial virus (RSV)/human metapneumovirus (hMPV) virus-like particle (VLP) candidate vaccine (IVX-A12) compared to placebo, when administered as a single-dose regimen in healthy older adults 60 to 85 years of age.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202420252026
Enrollment StartMay 2023
Primary CompletionJun 2023
First PostedJun 2023
Study CompletionOct 2024
TodayJul 2026
First PostedJun 15, 2023
Enrollment StartMay 15, 2023
Primary CompletionJun 5, 2023
Study CompletionOct 25, 2024
TodayJul 2, 2026
Enrollment to primary: 20 daysPosted 3.0 years ago
Interventions
IVX-A12biological
IVX-A12 without adjuvant
IVX-A12biological
IVX-A12 with adjuvant
Placebobiological
Diluent